4.0(top 5%)
impact factor
364(top 50%)
papers
13.4K(top 20%)
citations
64(top 10%)
h-index
4.2(top 5%)
impact factor
448
all documents
13.9K
doc citations
106(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1A Review of the Pharmacological and Clinical Profile of MirtazapineCNS Neuroscience & Therapeutics2001494
2Paracetamol: New Vistas of an Old DrugCNS Neuroscience & Therapeutics2006460
3Paroxetine: A ReviewCNS Neuroscience & Therapeutics2001352
4Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)CNS Neuroscience & Therapeutics2006331
5The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's DiseaseCNS Neuroscience & Therapeutics2003328
6Neuroprotective Effects of Edaravone: a Novel Free Radical Scavenger in Cerebrovascular InjuryCNS Neuroscience & Therapeutics2006324
7Lacosamide: A Review of Preclinical PropertiesCNS Neuroscience & Therapeutics2007316
8Valproate: Past, Present, and FutureCNS Neuroscience & Therapeutics2003274
9Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's DiseaseCNS Neuroscience & Therapeutics2002236
10Piracetam: A Review of Pharmacological Properties and Clinical UsesCNS Neuroscience & Therapeutics2005218
11Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation AgentCNS Neuroscience & Therapeutics2006217
12BMS‐204352: A Potassium Channel Opener Developed for the Treatment of StrokeCNS Neuroscience & Therapeutics2002201
13Moclobemide: Therapeutic Use and Clinical StudiesCNS Neuroscience & Therapeutics2003184
14The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical ProfileCNS Neuroscience & Therapeutics2004184
15Guanfacine and Guanfacine Extended Release: Treatment for ADHD and Related DisordersCNS Neuroscience & Therapeutics2007183
16The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous SystemCNS Neuroscience & Therapeutics2001178
17Phenibut (β‐Phenyl‐GABA): A Tranquilizer and Nootropic DrugCNS Neuroscience & Therapeutics2001173
18SCH 23390: The First Selective Dopamine D1‐Like Receptor AntagonistCNS Neuroscience & Therapeutics2001172
19Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's DiseaseCNS Neuroscience & Therapeutics2007166
20Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEPCNS Neuroscience & Therapeutics2006149
21A New Look at the 5?-Reductase Inhibitor FinasterideCNS Neuroscience & Therapeutics2006146
22Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust PharmacologyCNS Neuroscience & Therapeutics2004133
23Ginsenosides: Are Any of them Candidates for Drugs Acting on the Central Nervous System?CNS Neuroscience & Therapeutics2007132
24Ondansetron: A Selective 5‐HT3 Receptor Antagonist and Its Applications in CNS‐Related DisordersCNS Neuroscience & Therapeutics2001128
25Therapeutic Potential of Wogonin: A Naturally Occurring FlavonoidCNS Neuroscience & Therapeutics2005128
26The Pharmacology of PhysostigmineCNS Neuroscience & Therapeutics1998127
27NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP)CNS Neuroscience & Therapeutics2005127
28Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective AgonistsCNS Neuroscience & Therapeutics2003122
29Involvement of Calpain Activation in Neurodegenerative ProcessesCNS Neuroscience & Therapeutics2006117
30Retigabine: Chemical Synthesis to Clinical ApplicationCNS Neuroscience & Therapeutics2005115
31Pharmacology of FlibanserinCNS Neuroscience & Therapeutics2002114
32Role of Hyperforin in the Pharmacological Activities of St. John's WortCNS Neuroscience & Therapeutics2004114
33A New Look at the Respiratory Stimulant DoxapramCNS Neuroscience & Therapeutics2006114
34Augmentation Treatment of Psychotherapy for Anxiety Disorders with D-CycloserineCNS Neuroscience & Therapeutics2006111
35Ethosuximide: From Bench to BedsideCNS Neuroscience & Therapeutics2007111
36Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the LiteratureCNS Neuroscience & Therapeutics2004110
37A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor AgonistCNS Neuroscience & Therapeutics2003108
38TC‐1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long‐Lasting Cognitive EffectsCNS Neuroscience & Therapeutics2004104
39The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A ReviewCNS Neuroscience & Therapeutics2003100
40Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory DiseasesCNS Neuroscience & Therapeutics200798
41Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake InhibitorCNS Neuroscience & Therapeutics200697
42Pharmacological Actions of NGB 2904, a Selective Dopamine D 3 Receptor Antagonist, in Animal Models of Drug AddictionCNS Neuroscience & Therapeutics200796
43S 17092: A Prolyl Endopeptidase Inhibitor as a Potential Therapeutic Drug for Memory Impairment. Preclinical and Clinical StudiesCNS Neuroscience & Therapeutics200295
44Pharmacological Profile of Huperzine A, a Novel Acetylcholinesterase Inhibitor from Chinese HerbCNS Neuroscience & Therapeutics199994
45Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant DrugCNS Neuroscience & Therapeutics200791
46Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor AntagonistCNS Neuroscience & Therapeutics200590
47Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS DrugCNS Neuroscience & Therapeutics200689
48UFP‐101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ ReceptorCNS Neuroscience & Therapeutics200588
49Pharmacology of the β‐Carboline FG‐7142, a Partial Inverse Agonist at the Benzodiazepine Allosteric Site of the GABAA Receptor: Neurochemical, Neurophysiological, and Behavioral EffectsCNS Neuroscience & Therapeutics200787
502,3-Benzodiazepines (GYKI 52466 and Analogs): Negative Allosteric Modulators of AMPA ReceptorsCNS Neuroscience & Therapeutics199685